5 research outputs found
Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives
Analysis of the Glutamate Agonist LY404,039 Binding to Nonstatic Dopamine Receptor D2 Dimer Structures and Consensus Docking
Dopamine receptor D2 (D2R) plays
an important role in the human
central nervous system and is a focal target of antipsychotic agents.
The D2<sup>High</sup>R and D2<sup>Low</sup>R dimeric models previously
developed by our group are used to investigate the prediction of binding
affinity of the LY404,039 ligand and its binding mechanism within
the catalytic domain. The computational data obtained using molecular
dynamics simulations fit well with the experimental results. The calculated
binding affinities of LY404,039 using MM/PBSA for the D2<sup>High</sup>R and D2<sup>Low</sup>R targets were −12.04 and −9.11
kcal/mol, respectively. The experimental results suggest that LY404,039
binds to D2<sup>High</sup>R and D2<sup>Low</sup>R with binding affinities
(<i>K</i><sub>i</sub>) of 8.2 and 1640 nM, respectively.
The high binding affinity of LY404,039 in terms of binding to [<sup>3</sup>H]domperidone was inhibited by the presence of a guanine nucleotide,
indicating an agonist action of the drug at D2<sup>High</sup>R. The
interaction analysis demonstrated that while Asp114 was among the
most critical amino acids for D2<sup>High</sup>R binding, residues
Ser193 and Ser197 were significantly more important within the binding
cavity of D2<sup>Low</sup>R. Molecular modeling analyses are extended
to ensemble docking as well as structure-based pharmacophore model
(E-pharmacophore) development using the bioactive conformation of
LY404,039 at the binding pocket as a template and screening of small-molecule
databases with derived pharmacophore models
Analysis of the Glutamate Agonist LY404,039 Binding to Nonstatic Dopamine Receptor D2 Dimer Structures and Consensus Docking
Dopamine receptor D2 (D2R) plays
an important role in the human
central nervous system and is a focal target of antipsychotic agents.
The D2<sup>High</sup>R and D2<sup>Low</sup>R dimeric models previously
developed by our group are used to investigate the prediction of binding
affinity of the LY404,039 ligand and its binding mechanism within
the catalytic domain. The computational data obtained using molecular
dynamics simulations fit well with the experimental results. The calculated
binding affinities of LY404,039 using MM/PBSA for the D2<sup>High</sup>R and D2<sup>Low</sup>R targets were −12.04 and −9.11
kcal/mol, respectively. The experimental results suggest that LY404,039
binds to D2<sup>High</sup>R and D2<sup>Low</sup>R with binding affinities
(<i>K</i><sub>i</sub>) of 8.2 and 1640 nM, respectively.
The high binding affinity of LY404,039 in terms of binding to [<sup>3</sup>H]domperidone was inhibited by the presence of a guanine nucleotide,
indicating an agonist action of the drug at D2<sup>High</sup>R. The
interaction analysis demonstrated that while Asp114 was among the
most critical amino acids for D2<sup>High</sup>R binding, residues
Ser193 and Ser197 were significantly more important within the binding
cavity of D2<sup>Low</sup>R. Molecular modeling analyses are extended
to ensemble docking as well as structure-based pharmacophore model
(E-pharmacophore) development using the bioactive conformation of
LY404,039 at the binding pocket as a template and screening of small-molecule
databases with derived pharmacophore models
Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cell proliferation
AT1 antagonists is the most recent drug class of molecules against hypertension and they mediate their actions through blocking detrimental effects of angiotensin II (A-II) when acts on type I (AT1) A-II receptor. The effects of AT1 antagonists are not limited to cardiovascular diseases. AT1 receptor blockers may be used as potential anti-cancer agents - due to the inhibition of cell proliferation stimulated by A-II. Therefore, AT1 receptors and the A-II biosynthesis mechanisms are targets for the development of new synthetic drugs and therapeutic treatment of various cardiovascular and other diseases. In this work, multi-scale molecular modeling approaches were performed and it is found that oxazolone and imidazolone derivatives reveal similar/better interaction energy profiles compared to the FDA approved sartan molecules at the binding site of the AT1 receptor. In silico-guided designed hit molecules were then synthesized and tested for their binding affinities to human AT1 receptor in radioligand binding studies, using [I-125-Sar(1)-Ile(8)] AngII. Among the compounds tested, 19d and 9j molecules bound to receptor in a dose response manner and with relatively high affinities. Next, cytotoxicity and wound healing assays were performed for these hit molecules. Since hit molecule 19d led to deceleration of cell motility in all three cell lines (NIH3T3, A549, and H358) tested in this study, this molecule is investigated in further tests. In two cell lines (HUVEC and MCF-7) tested, 19d induced G2/M cell cycle arrest in a concentration dependent manner. Adherent cells detached from the plates and underwent cell death possibly due to apoptosis at 19d concentrations that induced cell cycle arrest. (C) 2017 Elsevier Masson SAS. All rights reserved